International Journal of Endocrinology / 2016 / Article / Tab 2

Research Article

Response to Radioiodine Therapy for Thyrotoxicosis: Disparate Outcomes for an Indigenous Population

Table 2

Baseline data by ethnicity.

Non-Māori ()Māori ()

Age14255 (52.6, 57.6)7150.4 (47.7, 53.1)0.0132

GenderF142116 (81.7%)7161 (85.9%)0.438
M26 (18.3%)10 (14.1%)

DiagnosisGD14298 (69.0%)7136 (50.7%)0.011
TMNG39 (27.5%)34 (47.9%)
STA5 (3.5%)1 (1.4%)

Weight (kg)13373.7 (52.2, 118.3)6781.4 (55.1, 118.1)0.0698

OphthalmopathyNil 9671 (74.0%)3625 (69.4%) 0.814
Mild18 (18.8%)7 (19.4%)
Mod.4 (4.2%)3 (8.3%)
Sev.3 (3.0%)1 (2.8%)

T4 at presentation13328 (12, 61)6830 (11, 74)0.2461

Pretreatment ATD142118 (83.1%)7166 (93.0%)0.048

Length of ATD (wks)11744 (9, 374)6652 (14, 504)0.4837

Posttreatment ATD11742 (35.9%)6528 (43.08%)0.34

Follow-up length (wks)142944 (428, 1459)71791 (432, 1481)0.1361

ATD: antithyroid medication; F: female; M: male; GD: Graves’s disease; TMNG: toxic multinodular goitre; STA: solitary toxic adenoma; Mod.: moderate eye disease; Sev.: severe eye disease.
Continuous variables are expressed as mean (95% confidence intervals) or median (5th, 95th percentile) according to their distribution. Categorical variables are expressed as number (percentage).

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.